Innodia Inc. is a privately held biotechnology company with the mission to develop and bring to the market novel drugs for the treatment of obesity, type 2 diabetes and associated diseases.

Type 2 diabetes is reaching epidemic levels with an estimated 190 million individuals affected worldwide. With skyrocketing obesity rates and an aging population, this epidemic is expected to grow rapidly and become a major burden on global healthcare resources.

In less than three years, Innodia’s pipeline has grown to include orally administered compounds to treat obesity and type 2 diabetes. These compounds have distinct and complementary mechanisms of action related to the stimulation of insulin secretion, the lowering of blood glucose, the preservation of pancreatic function and the increase metabolic energy expenditure.

AdyviaTM (ID 1101) is Innodia's lead anti-obesity drug candidate, now in Phase II clinical trials. In addition, several other antidiabetic and anti-obesity compounds are in earlier stages of development.